

国内版 国际版

g

Expected outcomes and patients' selection before chemoemboliz: X   

ALL IMAGES VIDEOS

6,650 Results Any time ▾

### [Safety and efficacy of sorafenib in hepatocellular ...](#)

<https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2036.2011.04860.x>

Sep 29, 2011 · Before treatment with sorafenib, patients may have received systemic chemotherapy or local treatment (surgical resection, radiofrequency ablation or transarterial chemoembolization). For each patient, sorafenib treatment (400 mg twice daily) was initiated after a multidisciplinary meeting according to French recommendations for treatment of cancer.

Cited by: 125 Author: A. Hollebecque, S. Cattan, O. Romano, ...

Publish Year: 2011

### [Tolerance and outcomes of sorafenib in elderly patients ...](#)

<https://www.sciencedirect.com/science/article/pii/S1590865817309386>

Sep 01, 2017 · Population based cohorts such as the GIDEON study (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma [HCC] and Of its treatment with sorafeNib), has provided outcomes of sorafenib in real-life worldwide, in patients treated for HCC with underlying cirrhosis scored Child-Pugh A, B and C . Therefore, data on the efficacy ...

Cited by: 9 Author: Nicolas Williet, Léa Clavel, Aurélie Bour...

Publish Year: 2017

### [Chemoembolization of Hepatocellular Carcinoma | Request PDF](#)

[https://www.researchgate.net/publication/259771391\\_Chemoembolization\\_of\\_Hepatocellular...](https://www.researchgate.net/publication/259771391_Chemoembolization_of_Hepatocellular...)

Request PDF | Chemoembolization of Hepatocellular Carcinoma | Transarterial chemoembolization (TACE) is the current standard of care for patients with intermediate-stage hepatocellular carcinoma ...

### [Assessment for Retreatment \(ART\) Score for Repeated ...](#)

[https://www.researchgate.net/publication/257648639\\_Assessment\\_for\\_Retreatment\\_ART...](https://www.researchgate.net/publication/257648639_Assessment_for_Retreatment_ART...)

Results: Before the second chemoembolization procedure, 22 patients (12%) showed an increase

国内版 国际版

Expected outcomes and patients' selection before chemoembolizat



ALL IMAGES VIDEOS

7,990 Results Any time ▾

### Safety and efficacy of sorafenib in hepatocellular ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2036.2011.04860.x>

Sep 29, 2011 · Before treatment with sorafenib, **patients may** have received systemic chemotherapy or local treatment (surgical resection, radiofrequency ablation or transarterial **chemoembolization**). For each **patient**, sorafenib treatment (400 mg twice daily) was initiated after a multidisciplinary meeting according to **French** recommendations for treatment of cancer.

**Cited by:** 128      **Author:** A. Hollebecque, S. Cattan, O. Romano, G. S...  
**Publish Year:** 2011

### Tolerance and outcomes of sorafenib in elderly patients ...

<https://www.sciencedirect.com/science/article/pii/S1590865817309386>

Sep 01, 2017 · Population based **cohorts** such as the GIDEON study (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma [HCC] and Of its treatment with sorafeNib), has provided **outcomes** of sorafenib in **real-life** worldwide, in **patients** treated for HCC with underlying cirrhosis scored Child-Pugh A, B and C . Therefore, data on the efficacy ...

**Cited by:** 9      **Author:** Nicolas Williet, Léa Clavel, Aurélie Bourmau...  
**Publish Year:** 2017

### Efficacy Outcome Selection in the Therapeutic Hypothermia ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396179>

**Selection of Secondary Outcomes.** Secondary efficacy **outcome selection** was based on two main considerations: inclusion of children with pre-arrest VABS-II scores below 70 who were excluded from the primary analysis, and incorporation of **outcomes** that would more clearly delineate any treatment benefits on survival versus improved VABS-II performance.

**Cited by:** 29      **Author:** Richard Holubkov, Amy E. Clark, Frank W. ...

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 60660

Manuscript Type: ORIGINAL ARTICLE

*Retrospective Cohort Study*

Expected outcomes and patients' selection before chemoembolization – "Six-and-Twelve or Pre-TACE-Predict" scores may help clinicians: Real-life French cohorts results

"Six-and-Twelve" or "Pre-TACE-Predict" scores before chemoembolization?

**Abstract**

**BACKGROUND**

Careful selection of hepatocellular carcinoma (HCC) patients prior to chemoembolization treatment is a daily reality, even more necessary with new available therapeutic options in HCC.

Match Overview

1	Internet 168 words crawled on 28-Dec-2020 <a href="http://atm.amegroups.com">atm.amegroups.com</a>	4%
2	Internet 62 words crawled on 02-Oct-2020 <a href="http://www.wjnet.com">www.wjnet.com</a>	2%
3	Crossref 34 words Xavier Adhoute, Guillaume Pénaranda, Jean-Luc Raoul, Olivia Pietri et al. "Hepatocellular carcinoma macroscopic g..."	1%
4	Internet 29 words crawled on 21-Oct-2020 <a href="http://www.researchsquare.com">www.researchsquare.com</a>	1%
5	Crossref 16 words Xavier Adhoute, Guillaume Pénaranda, Jean-Luc Raoul, Jean-Pierre Bronowicki, Rodolphe Anny, Marc Bourlière. "Six"	<1%
6	Internet 13 words crawled on 24-Nov-2019 <a href="http://journals.sagepub.com">journals.sagepub.com</a>	<1%
7	Crossref 12 words Filippo Pelizzaro, Barbara Penzo, Giulia Peserico, Angeli... mondi et al. "Monofocal hepatocellular carcinoma: how mu..."	<1%
8	Internet 12 words crawled on 31-Jan-2020 <a href="http://link.springer.com">link.springer.com</a>	<1%

国内版 国际版

Expected outcomes and patients' selection before chemoembolizati



ALL IMAGES VIDEOS

7,290 Results Any time ▾

## Outcome Measures | CMS

<https://www.cms.gov/.../OutcomeMeasures> ▾

Background. In the interest of promoting high-quality, patient-centered care and accountability, the Centers for Medicare & Medicaid Services (CMS) and Hospital Quality Alliance (HQA) began publicly reporting 30-day mortality measures for acute myocardial infarction (AMI) and heart failure (HF) in June 2007 and for pneumonia (PN) in June 2008.

## Efficacy Outcome Selection in the Therapeutic Hypothermia ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396179>

Selection of Secondary Outcomes. Secondary efficacy outcome selection was based on two main considerations: inclusion of children with pre-arrest VABS-II scores below 70 who were excluded from the primary analysis, and incorporation of outcomes that would more clearly delineate any treatment benefits on survival versus improved VABS-II performance.

Cited by: 29 Author: Richard Holubkov, Amy E. Clark, Frank ...

Publish Year: 2015

## Assessment for Retreatment (ART) Score for Repeated ...

<https://www.researchgate.net/publication/257648639...>

Results: Before the second chemoembolization procedure, 22 patients (12%) showed an increase of 1 point in Child-Pugh score and 51 patients (22%) had an increase of  $\geq 2$  points.

## Safety and efficacy of sorafenib in hepatocellular ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2036.2011.04860.x>

Sep 29, 2011 · Before treatment with sorafenib, patients may have received systemic chemotherapy or local treatment (surgical resection, radiofrequency ablation or transarterial chemoembolization). For each patient, sorafenib treatment (400 mg twice daily) was initiated after a multidisciplinary meeting according to French recommendations for treatment of cancer.

Cited by: 127 Author: A. Hollebecque, S. Cattan, O. Romano, ...

Publish Year: 2011

## Transarterial Chemoembolization and Radioembolization ...

<https://www.researchgate.net/publication/267813377...>

The short half-life (64.1 h) and limited tissue penetration (2.5-10 mm) of  $^{90}\text{Y}$  allow for dissipation within 2 weeks, and post-treatment isolation is not necessary [96].